DGIdb - CISPLATIN Drug Record

CISPLATIN chembl:CHEMBL11359 ApprovedAntineoplasticImmunotherapy

Alternate Names:

PLATINOL
CIS-DDP
INT-230-6 COMPONENT CISPLATIN
PLATINOL-AQ
CISPLATIN
CISPLATINUM
INT230-6 COMPONENT CISPLATIN
NSC-119875
CIS-PLATINUM II
CIS-DIAMMINEDICHLOROPLATINUM(II)
CDDP
rxcui:2555
chembl:CHEMBL11359
chemidplus:15663-27-1
drugbank:00515
pubchem.compound:5702198

Drug Info:

(9 More Sources)

Publications:

Xu et al., 2014, Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis., J Transl Med
Tamotsu et al., 2015, Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma., BMC Cancer
Clemens E et al., 2020, Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study., Pharmacogenomics J
Sawers et al., 2014, Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines., Br. J. Cancer
Goričar K et al., 2015, Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma., Cancer Epidemiol
Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
Booton R et al., 2006, Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer., J Thorac Oncol
Kimura S et al., 2004, The relationship of the human glutathione S-transferase P1 polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma., Int J Mol Med
Hour et al., Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines., Anticancer Res.
Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
Sheffield et al., 2015, Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing., PLoS ONE
Castagna et al., 2004, A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431., Proteomics
Hawinkels et al., 2016, Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., Clin. Cancer Res.
Sen et al., 2017, CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib., Cancer Res.
Gadhikar et al., 2013, Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53., Mol. Cancer Ther.
Carrillo et al., 2015, Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells., Mol. Cancer Res.
Chang et al., 2015, The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity., Mol. Cancer Ther.
Richer et al., 2017, WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer., Cancer Res.
Zhang et al., 2015, Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53., Cancer Res.
Han et al., 2008, Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer., Cancer
Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.
Michels et al., 2013, Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer., Cell Cycle
Fransson et al., 2016, Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer., J Ovarian Res
Mohell et al., 2015, APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells., Cell Death Dis
Zamble et al., 1998, p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells., Proc. Natl. Acad. Sci. U.S.A.
Nakata et al., 1996, [Association between p53 expression and chemosensitivity in advanced and recurrent gastric cancer]., Gan To Kagaku Ryoho
Kigawa et al., 2002, Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells., Gynecol. Oncol.
Reles et al., 2001, Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer., Clin. Cancer Res.
Bataille F et al., 2003, Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer., Mol Pathol
Zhang et al., 2013, Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer., Carcinogenesis
Kang et al., 2016, ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models., Lung Cancer
Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
Xu JL et al., 2012, Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population., Asian Pac J Cancer Prev
Sasano et al., 2015, Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary., Mol. Cancer Res.
Barni et al., 1987, Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients., Tumori
Xu X et al., 2012, Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients., Clin Exp Pharmacol Physiol
Xu X et al., 2012, Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients., Lung Cancer
Wang et al., 2003, [Study on the expression of DNA excision repair biomarkers in cispatin-treated lung cancer cell line]., Zhonghua Yu Fang Yi Xue Za Zhi
Caronia et al., 2009, Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients., Pharmacogenomics J.
Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
Lamas MJ et al., 2011, Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer., Pharmacogenomics
Drögemöller BI et al., 2017, Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer., JAMA Oncol
Spracklen TF et al., 2017, Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin., Pharmacogenomics J
Lanvers-Kaminsky C et al., 2015, Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity., Pharmacogenomics
Ciarimboli G et al., 2012, Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients., Clin Cancer Res
Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
Gately et al., 1996, Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153., Br. J. Cancer
Johnsson et al., 1999, Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts., Cancer Chemother. Pharmacol.
Maki et al., 2005, Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines., Oral Oncol.
Chen et al., 1994, O6-methylguanine-DNA methyltransferase in ovarian malignancy and its correlation with postoperative response to chemotherapy., Gynecol. Oncol.
Rosell et al., 2003, Targeted therapy in combination with gemcitabine in non-small cell lung cancer., Semin. Oncol.
Nie et al., 2013, The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer., Cancer Biomark
Ryu JS et al., 2011, Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum., J Thorac Oncol
Rosell R et al., 2004, Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
Choeyprasert W et al., 2013, Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms., J Pediatr Hematol Oncol
Riedemann L et al., 2008, Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin., Pharmacogenomics J
Han JY et al., 2010, Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy., Pharmacogenomics J
Mueller et al., 2003, Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer., Cancer Res.
Baltaci et al., 2001, P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours., BJU Int.
Chung et al., 2014, A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma., Ann. Oncol.
Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
Cui LH et al., 2011, Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC., Pharmacogenomics
Chen JS et al., 2010, A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma., Anticancer Drugs
Smit EF et al., 2009, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer., J Clin Oncol
Patiño-García A et al., 2009, Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression., J Pediatr
Arjumand et al., 2016, Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells., Oncotarget
Kool et al., 1997, Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines., Cancer Res.
Han JY et al., 2014, A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy., Pharmacogenomics J
Sulkowski et al., 2017, 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity., Sci Transl Med
Raaphorst et al., 2005, Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair., Oncol. Rep.
Nylén et al., 1998, Cisplatin-induced inhibition of p34cdc2 is abolished by 5-fluorouracil., Acta Oncol
Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
Newman et al., 1988, Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin., Biochem. Pharmacol.
Cui et al., 2012, Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity., Clin. Cancer Res.
Chen et al., 2000, [Establishment of cisplatin-induced multidrug resistant human epithelial ovarian cancer cell line 3AO/cDDP and its expressions of multidrug resistance proteins]., Zhonghua Fu Chan Ke Za Zhi
Alakus et al., 2009, GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer., Pharmacogenomics J.
Jaboin et al., 2002, Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway., Cancer Res.
Brozovic et al., 2001, Induction of heat shock protein 70 in drug-resistant cells by anticancer drugs and hyperthermia., Neoplasma
Li et al., 1998, Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells., Int. J. Oncol.
Li et al., Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line., Anticancer Res.
Goldberg et al., 2001, An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin., Int. J. Radiat. Oncol. Biol. Phys.
Li et al., Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells., Anticancer Res.
Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
Rumiato E et al., 2013, ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy., Pharmacogenet Genomics
Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
Kim HS et al., 2009, Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study., Gynecol Oncol
Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
Kawashima et al., 2011, Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer., Clin. Cancer Res.
Usanova et al., 2010, Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression., Mol. Cancer
Postel-Vinay et al., 2013, A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer., Oncogene
Cheng et al., 2013, PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells., Carcinogenesis
Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
Ceppi P et al., 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine., Ann Oncol
Rosell et al., 2006, Pharmacogenomics and gemcitabine., Ann. Oncol.
Kerley-Hamilton et al., 2005, A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma., Oncogene
Clark et al., 1994, Effect of interferon gamma and tumour necrosis factor alpha on sensitivity to cisplatin in ovarian carcinoma cell lines., Cancer Immunol. Immunother.
Samimi et al., 2004, Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B., Mol. Pharmacol.
Miyashita et al., 2003, Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin., Oral Oncol.
Nakayama et al., Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines., Oncol. Rep.
Xing et al., 2006, A mouse model for the molecular characterization of brca1-associated ovarian carcinoma., Cancer Res.
Wang et al., 2016, RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance., J. Clin. Invest.
Golan T et al., 2014, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers., Br J Cancer
de Jong C et al., 2017, Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman., Br J Clin Pharmacol
Thiesen S et al., 2017, TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity., Pharmacogenet Genomics
Hagleitner MM et al., 2014, Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts., PLoS One
Carleton BC et al., 2014, Genetic markers of cisplatin-induced hearing loss in children., Clin Pharmacol Ther
Lanvers-Kaminsky C et al., 2014, Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity., Clin Pharmacol Ther
Yang JJ et al., 2013, The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer., Clin Pharmacol Ther
Pussegoda K et al., 2013, Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children., Clin Pharmacol Ther
Ross CJ et al., 2009, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy., Nat Genet
Khrunin AV et al., 2014, Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer., Pharmacogenomics
Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
Olas et al., 1998, Modulation of cisplatin toxicity in blood platelets by glutathione depletion., Anticancer Drugs
Go et al., 1997, Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro., Clin. Exp. Metastasis
Vendetti et al., 2015, The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo., Oncotarget
Nakayama et al., 2005, Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets., J. Pharmacol. Sci.
Iida et al., 1999, Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells., Int. J. Cancer
van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
Siegsmund et al., 1999, Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins., Urol. Res.
Watanabe et al., 2003, Expression of caspase-activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigs., Auris Nasus Larynx
O'Donnell PH et al., 2016, Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer., Clin Genitourin Cancer
O'Flaherty et al., 2002, Cytotoxicity of paclitaxel or cisplatin on carcinoma cell lines is not inhibited by leukemia inhibitory factor (LIF)., Growth Factors
Boyle et al., 2001, The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin., Cancer Chemother. Pharmacol.
Smith et al., 1997, The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity., Exp. Cell Res.
Smith et al., 2000, p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes., Mol. Cell. Biol.
Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
Yazlovitskaya et al., Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin., Anticancer Res.
Cao et al., 2008, Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling., Carcinogenesis
Nam et al., 2016, Src as a Therapeutic Target in Biliary Tract Cancer., Mol. Cancer Ther.
Nomura et al., Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells., Urol. Oncol.
Li et al., 2001, Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins., Endocrinology
Cho et al., 2008, Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance., Cancer Lett.
Patrick et al., 1997, High-mobility group 1 protein inhibits helicase catalyzed displacement of cisplatin-damaged DNA., Biochim. Biophys. Acta
Kawahara et al., 1996, Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin., Cancer Res.
Vos HI et al., 2016, Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma., Pharmacogenet Genomics
Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J
Liang KH et al., 2011, GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC., Pharmacogenomics
Kiyozuka et al., Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells., Anticancer Res.
Romerius P et al., 2011, Estrogen receptor α single nucleotide polymorphism modifies the risk of azoospermia in childhood cancer survivors., Pharmacogenet Genomics
Moers et al., 1999, Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin., Int. J. Cancer
Yilmaz et al., 2004, The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats., Pharmacol. Res.
Okegawa et al., 2004, Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer., J. Urol.
Yang Z et al., 2018, Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy., EBioMedicine
Xie X et al., 2019, FGFR<sup>3S249C</sup> mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells., Exp Ther Med
Sakano S et al., 2010, Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer., Pharmacogenomics
Beretta et al., Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells., Ultrastruct Pathol
Russo et al., 2006, E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents., Cancer Res.
Bell et al., 2016, SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer., Clin. Cancer Res.
Zhang et al., 2006, Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line., BMC Cancer
Hegde et al., 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer., Sci Transl Med
Ghazizadeh, 2003, Cisplatin may induce frataxin expression., J Nippon Med Sch
Li et al., 2000, [Effects of the expression of mouse metallothionein-I gene in human HeLa cell line on drug resistance]., Wei Sheng Yan Jiu
Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med
Yamaguchi et al., 2007, Serum progastrin-releasing peptide levels followed by whole-body positron emission tomography detects early recurrence of small-cell lung cancer., Respirology
van Hensbergen et al., 2004, Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts., Clin. Cancer Res.
Ding et al., 2013, Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells., Tumour Biol.
Scartozzi M et al., 2013, Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients., Pharmacogenomics
Mutze et al., 2011, DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer., Eur. J. Cancer
Shirasaka, 1990, [Clinical study of nephrotoxicity following cis-diamminedichloroplatinum (II) (CDDP) combination chemotherapy assessed by 131I-OIH renogram]., Nihon Igaku Hoshasen Gakkai Zasshi
Kotoh et al., 1994, Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells., Cancer Res.
Schmeiser et al., 1999, The fate of E- and P-cadherin during the early stages of apoptosis., Cell Death Differ.
Spracklen TF et al., 2014, Genetic variation in Otos is associated with cisplatin-induced ototoxicity., Pharmacogenomics
Medeiros et al., 2003, Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome., Int. J. Clin. Oncol.
Lee et al., 2005, Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line., Gynecol. Oncol.
Mimnaugh et al., 2000, Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors., Biochem. Pharmacol.
Xu X et al., 2013, The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients., Lung Cancer
Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Wu H et al., 2013, Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis., Pharmacogenomics
Narumiya K et al., 2011, Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer., Pharmacogenomics
McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
Ono et al., 2001, Loss of p73 induction in a cisplatin-resistant bladder cancer cell line., Mol Urol
Kolesar JM et al., 2002, Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue., Int J Oncol
Beltran et al., 2015, Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response., JAMA Oncol
Suchi K et al., 2011, Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells., Anticancer Res
Gao W et al., 2012, MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer., Cancer Biol Ther
Xie et al., 2017, CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner., Oncol. Rep.
Roberts D et al., 2005, Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells., Br J Cancer

CISPLATIN LRP2

Interaction Score: 1.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31666714 23274376 17457342

Sources:
PharmGKB
CISPLATIN OTOS

Interaction Score: 1.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31666714 25410892

Sources:
PharmGKB
CISPLATIN XPC

Interaction Score: 1.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21047201 19434073

Sources:
PharmGKB
CISPLATIN ACYP2

Interaction Score: 1.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31666714 26928270

Sources:
PharmGKB
CISPLATIN MIR21

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22237007

Sources:
CIViC
CISPLATIN CSNK2A3

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27150640

Sources:
PharmGKB
CISPLATIN KRT20

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15017198

Sources:
NCI
CISPLATIN RARS1

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27150640

Sources:
PharmGKB
CISPLATIN DRAM1

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15940259

Sources:
NCI
CISPLATIN SLC16A5

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31666714

Sources:
PharmGKB
CISPLATIN ERCC1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration ERCC1:.

Alteration ERCC1:del

PMIDs:
9772291 9703867 11163512 10810335 29662106 27498158 25069034 23962907 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 19203783 18347182 21177407 20846399 23934192 23275151 17229776 16980606 16807441

Sources:
NCI CGI CIViC PharmGKB
CISPLATIN KLC3

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 22188361 22026922 21449681 19434073

Sources:
PharmGKB
CISPLATIN SLC31A1

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22725681 22516052

Sources:
PharmGKB
CISPLATIN MTR

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 21605004 19159907

Sources:
PharmGKB
CISPLATIN ERCC2

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration ERCC2:.

Drug family Chemotherapy

PMIDs:
12839662 19434073 29662106 22188361 22026922 21449681

Sources:
NCI CGI CIViC PharmGKB OncoKB
CISPLATIN SLC22A2

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28448657 27457817 25823781 22223530 21902499

Sources:
PharmGKB
CISPLATIN FANCA

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26181256

Sources:
CIViC
CISPLATIN EIF3A

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23127338

Sources:
PharmGKB
CISPLATIN MLLT3

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27150640

Sources:
PharmGKB
CISPLATIN MT1F

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12520915

Sources:
NCI
CISPLATIN FXN

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12928720

Sources:
NCI
CISPLATIN LIG3

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24533712

Sources:
PharmGKB
CISPLATIN MUTYH

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24533712

Sources:
PharmGKB
CISPLATIN MDH2

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15225672

Sources:
NCI
CISPLATIN TERC

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10769656

Sources:
NCI
CISPLATIN GALNT18

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27150640

Sources:
PharmGKB
CISPLATIN DFFB

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12927282

Sources:
NCI
CISPLATIN MT1H

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10422815

Sources:
NCI
CISPLATIN ERCC4

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration ERCC4:.

PMIDs:
None found

Sources:
CGI
CISPLATIN REV1

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CISPLATIN DCBLD1

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23478653

Sources:
PharmGKB
CISPLATIN UBE2I

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19859084

Sources:
PharmGKB
CISPLATIN ATP7B

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15213293 12509969 11605050

Sources:
NCI
CISPLATIN GALNT14

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31611591 21635146

Sources:
PharmGKB
CISPLATIN CDH17

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10381631

Sources:
NCI
CISPLATIN CMPK1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21642870

Sources:
PharmGKB
CISPLATIN BIRC7

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23188704

Sources:
CIViC
CISPLATIN GABPA

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18036733

Sources:
NCI
CISPLATIN GPX5

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CISPLATIN GCLM

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10399958

Sources:
NCI
CISPLATIN GADD45A

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9013707 10779360

Sources:
NCI
CISPLATIN FANCC

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration FANCC:.

Alteration FANCC:del

PMIDs:
16243825

Sources:
CGI CIViC
CISPLATIN RRM1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12917817 24595080 21642870 14977831

Sources:
NCI CIViC PharmGKB
CISPLATIN H2AW

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11008128

Sources:
NCI
CISPLATIN PPP1R13L

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CISPLATIN POLR1G

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CISPLATIN GCLC

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9660546

Sources:
NCI
CISPLATIN CDC25C

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9743457

Sources:
NCI
CISPLATIN TP73

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11689148

Sources:
NCI
CISPLATIN ADH1C

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24533712

Sources:
PharmGKB
CISPLATIN XRCC5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15944802

Sources:
NCI
CISPLATIN STAT1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15726096

Sources:
CIViC
CISPLATIN ACSS2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CISPLATIN AQP9

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12396244

Sources:
NCI
CISPLATIN ERCC6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration ERCC6:.

PMIDs:
None found

Sources:
CGI
CISPLATIN REV3L

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CISPLATIN COMT

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28560854 28448657 28445188 25551397 25141953 24642735 23820299 23588304 19898482

Sources:
PharmGKB
CISPLATIN GRP

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17207039

Sources:
NCI
CISPLATIN SMARCA4

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26671993

Sources:
CIViC
CISPLATIN EPHX1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24533712

Sources:
PharmGKB
CISPLATIN MTHFR

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 27995989 21605004 20634689 19307503 19159907

Sources:
PharmGKB
CISPLATIN BRCA2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration BRCA2:.

Drug family PARP inhibitor;Chemotherapy

combination therapy Veliparib;Cisplatin

PMIDs:
25193512 26801247 29338080 25847936

Sources:
JAX-CKB CGI CIViC
CISPLATIN HMGB1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9427537 8968078

Sources:
NCI
CISPLATIN LIF

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12519017 11800022

Sources:
NCI
CISPLATIN MAP3K1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CISPLATIN GSTP1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25010864 31666714 25592234 22188361 19786980 17409936 15254763 11062746

Sources:
NCI CIViC PharmGKB
CISPLATIN HEXB

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2089371

Sources:
NCI
CISPLATIN GSTA1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22188361

Sources:
PharmGKB
CISPLATIN TPMT

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration TPMT:.

Alteration TPMT:A80P,Y240C,A154T,A167G

PMIDs:
None found

Sources:
CGI FDA
CISPLATIN MYCN

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12439032

Sources:
NCI
CISPLATIN GSTT1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12851839

Sources:
NCI
CISPLATIN ATR

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12894503

Sources:
NCI
CISPLATIN XRCC1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16875718

Sources:
CIViC
CISPLATIN ABCC3

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31666714 27457817 25141953 22016816

Sources:
PharmGKB
CISPLATIN ANPEP

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14871998

Sources:
NCI
CISPLATIN SLC19A1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16875718

Sources:
PharmGKB
CISPLATIN SMAD4

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type pancreatic cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
22753594

Sources:
JAX-CKB
CISPLATIN NF2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25798586

Sources:
CIViC
CISPLATIN MGMT

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16043385 8314134

Sources:
NCI
CISPLATIN XIAP

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15610860 11145600

Sources:
NCI
CISPLATIN HSPA8

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15378690

Sources:
NCI
CISPLATIN ABCC4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9270026 23478653

Sources:
NCI PharmGKB
CISPLATIN E2F1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16849574

Sources:
NCI
CISPLATIN BRCA1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib;Cisplatin

Drug family PARP inhibitor;Chemotherapy

Alteration BRCA1:.

PMIDs:
16982732 27454289 26801247 25193512 29338080 25072261 25847936

Sources:
ClearityFoundationBiomarkers JAX-CKB NCI CGI CIViC
CISPLATIN IFNG

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8044830

Sources:
NCI
CISPLATIN DDIT3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8554977 10071988

Sources:
NCI
CISPLATIN NAT2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24533712

Sources:
PharmGKB
CISPLATIN FAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9935158

Sources:
NCI
CISPLATIN CXCR4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27922681

Sources:
CIViC
CISPLATIN NQO1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12370763

Sources:
PharmGKB
CISPLATIN TGM2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18667446

Sources:
NCI
CISPLATIN BCL2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12543810 11350408

Sources:
ClearityFoundationBiomarkers NCI
CISPLATIN CYP2E1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22188361

Sources:
PharmGKB
CISPLATIN STK11

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical

Evidence Type Actionable

Approval Status Preclinical - Cell culture

PMIDs:
28652249

Sources:
JAX-CKB
CISPLATIN NRG1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23390248

Sources:
CIViC
CISPLATIN IL6

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21273582

Sources:
CIViC
CISPLATIN PLAU

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9219734

Sources:
NCI
CISPLATIN RAF1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CISPLATIN DNMT1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21458988

Sources:
CIViC
CISPLATIN HTR4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16079468

Sources:
NCI
CISPLATIN HSPA4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11478701

Sources:
NCI
CISPLATIN PRL

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2953096

Sources:
NCI
CISPLATIN AURKA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25082261 25924824

Sources:
CIViC
CISPLATIN MDM2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration MDM2:amp

PMIDs:
None found

Sources:
CGI
CISPLATIN ATM

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6738 + Cisplatin

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
26517239

Sources:
JAX-CKB CGI
CISPLATIN GNAS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19274060

Sources:
CIViC
CISPLATIN CHEK1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28490518

Sources:
CIViC
CISPLATIN AKT1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Perifosine

Indication/Tumor Type ovarian clear cell carcinoma

Response Type predicted – sensitive

PMIDs:
22901187 25519148

Sources:
JAX-CKB PharmGKB
CISPLATIN TYMS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3337743

Sources:
NCI
CISPLATIN VEGFA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24090479

Sources:
PharmGKB
CISPLATIN TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy APR-246 + Cisplatin

Indication/Tumor Type lung small cell carcinoma

Response Type sensitive

PMIDs:
23839309 25964101 25376608 28652249 26294215 18618574 25567130 23428903 27179933 26086967 9600935 8678559 11812076 11595686 14514923

Sources:
JAX-CKB NCI CGI CIViC
CISPLATIN MYC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28490518

Sources:
CIViC
CISPLATIN FGFR3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29941343 31316618

Sources:
CIViC
CISPLATIN NTRK2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12438277

Sources:
NCI
CISPLATIN RB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration RB1:.

Alteration RB1:del

PMIDs:
None found

Sources:
CGI
CISPLATIN BAX

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15790433

Sources:
NCI
CISPLATIN NRAS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CISPLATIN ABCC1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11372415

Sources:
NCI
CISPLATIN KRAS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MK-1775 + Cisplatin

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

PMIDs:
25081901 27040853 28652249

Sources:
JAX-CKB CIViC
CISPLATIN ALK

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dalantercept + Cisplatin

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
26373572

Sources:
JAX-CKB
CISPLATIN SRC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bosutinib + Cisplatin

Indication/Tumor Type biliary tract cancer

Response Type sensitive

PMIDs:
27196758

Sources:
JAX-CKB
CISPLATIN G6PD

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15225672

Sources:
NCI
CISPLATIN PIK3CA

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type predicted – resistant

PMIDs:
27489350

Sources:
JAX-CKB CIViC PharmGKB
CISPLATIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 23746184 22016816 21332314 20530282

Sources:
PharmGKB
CISPLATIN RAD52

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24533712

Sources:
PharmGKB
CISPLATIN EGFR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ER2 + Cisplatin

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
23764753 27040853

Sources:
JAX-CKB CIViC
CISPLATIN FGFR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Etoposide + GSK3052230

Indication/Tumor Type lung small cell carcinoma

Response Type sensitive

PMIDs:
23536011

Sources:
JAX-CKB
CISPLATIN TOP1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8205547

Sources:
NCI
CISPLATIN ABCC2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CISPLATIN RECQL

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16978399

Sources:
NCI
CISPLATIN RGS4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN PTEN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CISPLATIN ESR1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21430602

Sources:
PharmGKB
CISPLATIN NR1I2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CISPLATIN MPHOSPH8

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN KAT2A

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN ALOX15

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN ERBB2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Gemcitabine + Sorafenib

Indication/Tumor Type invasive bladder transitional cell carcinoma

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
CISPLATIN APEX1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN CBX1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN IDH1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Talazoparib

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
28148839

Sources:
JAX-CKB
CISPLATIN HPGD

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN KDM4E

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN ALDH1A1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN HSD17B10

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN MAPT

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

NCI: CISPLATIN

Version: 14-September-2017

Alternate Names:

C376 NCI drug code

Drug Info:

Publications:

Castagna et al., 2004, A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431., Proteomics

Kool et al., 1997, Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines., Cancer Res.

Raaphorst et al., 2005, Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair., Oncol. Rep.

NCI: CISPLATINUM

Version: 14-September-2017

Alternate Names:

C376 NCI drug code

Drug Info:

Publications:

Medeiros et al., 2003, Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome., Int. J. Clin. Oncol.

NCI: CDDP

Version: 14-September-2017

Alternate Names:

C376 NCI drug code

Drug Info:

Publications:

Kiyozuka et al., Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells., Anticancer Res.

Chen et al., 2000, [Establishment of cisplatin-induced multidrug resistant human epithelial ovarian cancer cell line 3AO/cDDP and its expressions of multidrug resistance proteins]., Zhonghua Fu Chan Ke Za Zhi

Ono et al., 2001, Loss of p73 induction in a cisplatin-resistant bladder cancer cell line., Mol Urol

CGI: Cisplatin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Cheng et al., 2013, PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells., Carcinogenesis

Postel-Vinay et al., 2013, A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer., Oncogene

Kawashima et al., 2011, Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer., Clin. Cancer Res.

JAX-CKB: Cisplatin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Hawinkels et al., 2016, Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., Clin. Cancer Res.

Chang et al., 2015, The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity., Mol. Cancer Ther.

Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.

PharmGKB: cisplatin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Clemens E et al., 2020, Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study., Pharmacogenomics J

Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res

Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics

CIViC: CISPLATIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Arjumand et al., 2016, Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells., Oncotarget

Tamotsu et al., 2015, Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma., BMC Cancer

Xu et al., 2014, Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis., J Transl Med

DTC: CISPLATIN
- Version: 02-September-2020
Alternate Names:

CHEMBL11359 ChEMBL Drug ID

CHEMBL2068237 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Cisplatin
- Version: 2020.06.01
Alternate Names:

D0U5HU TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL11359
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: CISPLATIN
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
OncoKB: Cisplatin
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
FDA: Cisplatin
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Alteration	BRCA2:.
Drug family	PARP inhibitor;Chemotherapy
combination therapy	Veliparib;Cisplatin

Drug family	Chemotherapy
Alteration	TPMT:.
Alteration	TPMT:A80P,Y240C,A154T,A167G

Indication/Tumor Type	pancreatic cancer
Response Type	sensitive
Approval Status	Preclinical

Approval Status	Preclinical
Evidence Type	Actionable
Approval Status	Preclinical - Cell culture

combination therapy	AZD6738 + Cisplatin
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

combination therapy	Cisplatin + Perifosine
Indication/Tumor Type	ovarian clear cell carcinoma
Response Type	predicted – sensitive

combination therapy	APR-246 + Cisplatin
Indication/Tumor Type	lung small cell carcinoma
Response Type	sensitive

combination therapy	MK-1775 + Cisplatin
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	predicted – sensitive

combination therapy	Dalantercept + Cisplatin
Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive

combination therapy	Bosutinib + Cisplatin
Indication/Tumor Type	biliary tract cancer
Response Type	sensitive

combination therapy	ER2 + Cisplatin
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

combination therapy	Cisplatin + Etoposide + GSK3052230
Indication/Tumor Type	lung small cell carcinoma
Response Type	sensitive

combination therapy	Cisplatin + Gemcitabine + Sorafenib
Indication/Tumor Type	invasive bladder transitional cell carcinoma
Response Type	predicted – sensitive

combination therapy	Cisplatin + Talazoparib
Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive

CISPLATIN Drug Record

CISPLATIN chembl:CHEMBL11359 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31666714 23274376 17457342

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31666714 25410892

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21047201 19434073

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31666714 26928270

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22237007

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27150640

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15017198

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27150640

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15940259

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31666714

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Drug family Chemotherapy Alteration ERCC1:. Alteration ERCC1:del

PMIDs: 9772291 9703867 11163512 10810335 29662106 27498158 25069034 23962907 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 19203783 18347182 21177407 20846399 23934192 23275151 17229776 16980606 16807441

Sources: NCI CGI CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 22188361 22026922 21449681 19434073

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22725681 22516052

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 21605004 19159907

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Alteration ERCC2:. Drug family Chemotherapy

PMIDs: 12839662 19434073 29662106 22188361 22026922 21449681

Sources: NCI CGI CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28448657 27457817 25823781 22223530 21902499

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26181256

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23127338

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27150640

Interaction Types & Directionality:

n/a

PMIDs:
31666714 23274376 17457342

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31666714 25410892

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21047201 19434073

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31666714 26928270

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22237007

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
27150640

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15017198

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27150640

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15940259

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
31666714

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration ERCC1:.

Alteration ERCC1:del

PMIDs:
9772291 9703867 11163512 10810335 29662106 27498158 25069034 23962907 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 19203783 18347182 21177407 20846399 23934192 23275151 17229776 16980606 16807441

Sources:
NCI CGI CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29662106 22188361 22026922 21449681 19434073

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22725681 22516052

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29662106 21605004 19159907

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration ERCC2:.

Drug family Chemotherapy

PMIDs:
12839662 19434073 29662106 22188361 22026922 21449681

Sources:
NCI CGI CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
28448657 27457817 25823781 22223530 21902499

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26181256

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
23127338

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27150640

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12520915

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12928720

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24533712

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24533712

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15225672

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10769656

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27150640

Sources:
PharmGKB